Free Trial
→ Bill Gates’ is about to mint millionaires (again) with Stargate. (From Brownstone Research) (Ad)

Biofrontera Q4 2023 Earnings Report

Biofrontera logo
$1.02 -0.08 (-7.27%)
As of 04:00 PM Eastern
Earnings HistoryForecast

Biofrontera EPS Results

Actual EPS
-$2.33
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Biofrontera Revenue Results

Actual Revenue
$10.60 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Biofrontera Announcement Details

Quarter
Q4 2023
Date
3/15/2024
Time
N/A

Conference Call Resources

Biofrontera Earnings Headlines

Biofrontera Inc. files to sell 5.72M shares of common stock for holders
January 21 at 4:58 PM | markets.businessinsider.com
Biofrontera Inc. Announces Achievement of Key Milestone In Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) In The Treatment Of Superficial Basal Cell Carcinoma (sBCC)
January 8, 2025 | globenewswire.com
Bill Gates’ is about to mint millionaires (again) with Stargate.
This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrough so advanced, it’s going to make ChatGPT look like VHS. But what’s even more unbelievable? I believe it’ll make Nvidia’s meteoric rise look like a backyard bottle rocket.
January 21, 2025 | Brownstone Research (Ad)
Biofrontera announces 100 RhodoLED XL machines placed in U.S. market
December 24, 2024 | markets.businessinsider.com
Biofrontera Inc. Announces 100 RhodoLED® XL Machines Now Placed in US Market
December 23, 2024 | globenewswire.com
Biofrontera Inc. to Present at The Benchmark Company's Upcoming Discovery One-on-One Investor Conference
December 3, 2024 | finance.yahoo.com
See More Biofrontera Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Biofrontera? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Biofrontera and other key companies, straight to your email.

About Biofrontera

Biofrontera (NASDAQ:BFRI), a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. It offers Ameluz, a prescription drug for use in combination with the RhodoLED lamp series, for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. The company also provides Xepi, a topical non-fluorinated quinolone that inhibits bacterial growth for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.

View Biofrontera Profile

More Earnings Resources from MarketBeat

Earnings Tools
Earnings By Country
Latest Articles